ArticlePloS one2012
Exploiting adaptive laboratory evolution of Streptomyces clavuligerus for antibiotic discovery and overproduction.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 95 citations in OpenAlex.
- Unlocking the Bioactive Potential of Streptomyces: A Multidisciplinary Approach to Strain Improvement.MicrobiologyOpen · 2026Review
- A comprehensive review of genomic-scale genetic engineering as a strategy to improve bacterial productivity.Microbiology (Reading, England) · 2025Review
- A new antifungal compound from Streptomyces diastatochromogenes.BMC biotechnology · 2025Article
- Genomic and Metabolomic Analyses ofMicroorganisms · 2025Article
- Probing interspecies metabolic interactions within a synthetic binary microbiome using genome-scale modeling.Microbiome research reports · 2024Article
- Investigating quorum-quenching marine bacilli as potential biocontrol agents for protection of shrimps against Early Mortality Syndrome (EMS).Scientific reports · 2023Article
- Adaptive Laboratory Evolution of Microorganisms: Methodology and Application for Bioproduction.Microorganisms · 2022Review
- Overview on Strategies and Assays for Antibiotic Discovery.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Evolving antibiotic spectrum.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Improvement of macrolactins production by the genetic adaptation of Bacillus siamensis A72 to saline stress via adaptive laboratory evolution.Microbial cell factories · 2022Article
- Adaptive laboratory evolution triggers pathogen-dependent broad-spectrum antimicrobial potency in Streptomyces.Journal, genetic engineering & biotechnology · 2022Article
- Streptomyces clavuligerus: The Omics Era.Journal of industrial microbiology & biotechnology · 2021Article
- Genome editing reveals that pSCL4 is required for chromosome linearity inMicrobial genomics · 2021Article
- Discovery of novel secondary metabolites encoded in actinomycete genomes through coculture.Journal of industrial microbiology & biotechnology · 2021Review
- Clinically relevant mutations in core metabolic genes confer antibiotic resistance.Science (New York, N.Y.) · 2021Article
- Elicitation of Antimicrobial Active Compounds byMicroorganisms · 2021Article
- Towards the sustainable discovery and development of new antibiotics.Nature reviews. Chemistry · 2021Review
- Current Status and Applications of Adaptive Laboratory Evolution in Industrial Microorganisms.Journal of microbiology and biotechnology · 2020Review
- Genome rearrangements and megaplasmid loss in the filamentous bacterium Kitasatospora viridifaciens are associated with protoplast formation and regeneration.Antonie van Leeuwenhoek · 2020Article
- Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development?mBio · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Adaptation is normally viewed as the enemy of the antibiotic discovery and development process because adaptation among pathogens to antibiotic exposure leads to resistance. We present a method here that, in contrast, exploits the power of adaptation among antibiotic producers to accelerate the discovery of antibiotics. A competition-based adaptive laboratory evolution scheme is presented whereby an antibiotic-producing microorganism is competed against a target pathogen and serially passed over time until the producer evolves the ability to synthesize a chemical entity that inhibits growth of the pathogen. When multiple Streptomyces clavuligerus replicates were adaptively evolved against methicillin-resistant Staphylococcus aureus N315 in this manner, a strain emerged that acquired the ability to constitutively produce holomycin. In contrast, no holomycin could be detected from the unevolved wild-type strain. Moreover, genome re-sequencing revealed that the evolved strain had lost pSCL4, a large 1.8 Mbp plasmid, and acquired several single nucleotide polymorphisms in genes that have been shown to affect secondary metabolite biosynthesis. These results demonstrate that competition-based adaptive laboratory evolution can constitute a platform to create mutants that overproduce known antibiotics and possibly to discover new compounds as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.